Skip to main content
SpringerLink
Log in

Serum visfatin levels do not increase in post-menopausal women with metabolic syndrome

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: The aim of this study was to determine the serum visfatin levels in post-menopausal (PM) women with and without metabolic syndrome (MS) and to understand the correlation between serum visfatin levels and various other hormonal and metabolic parameters. Materials-Methods: We conducted a prospective cross-sectional study including 17 PM women with MS and a control group of 51 PM women without MS. MS was defined according to the National Cholesterol Education Program Adult Treatment Panel III. Results: Women with MS had statistically significantly higher fasting blood glucose, HDL, triglycerides, insulin, homeostasis model assessment of insulin resistance, and SHBG levels when compared to women without MS. Estradiol, high sensitivity C-reactive protein, and free testosterone levels were higher in the MS group, but there was no statistically significant difference between the two groups. Visfatin levels did not differ between the two groups. There was no correlation between serum visfatin levels and other parameters. Conclusions: There was no association between serum visfatin levels and MS in PM women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285: 2486–97.

    Article  Google Scholar 

  2. Sherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006, 55: 1537–45.

    Article  CAS  Google Scholar 

  3. MacLaren R, Cui W, Cianflone K. Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Metab 2007, 9: 490–7.

    Article  PubMed  CAS  Google Scholar 

  4. Samal B, Sun Y, Stearns G, Xie C, Suggs S, Mc Niece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994, 14: 1431–7.

    PubMed Central  PubMed  CAS  Google Scholar 

  5. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307: 426–30.

    Article  PubMed  CAS  Google Scholar 

  6. Chen CC, Li TC, Li CI, et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 2007, 56: 1216–20.

    Article  PubMed  CAS  Google Scholar 

  7. Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008, 38: 71–2.

    Article  PubMed  CAS  Google Scholar 

  8. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998, 280: 1843–8.

    Article  PubMed  CAS  Google Scholar 

  9. Kim JH, Kim SH, IM JA, Lee DC. The relationship between visfatin and metabolic syndrome in postmenopausal women. Maturitas 2010, 67: 67–71.

    Article  PubMed  CAS  Google Scholar 

  10. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008, 69: 878–84.

    Article  CAS  Google Scholar 

  11. Lin CC, Lai MM, Li TC, et al. Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome. Diabetes Res Clin Pract 2009, 85: 24–9.

    Article  PubMed  CAS  Google Scholar 

  12. Ersoy C, Sadikoglu G, Orhan H, et al. Body fat distribution has no effect on serum visfatin levels in healthy female subjects. Cytokine 2010, 49: 275–8.

    Article  PubMed  CAS  Google Scholar 

  13. Berndt J, Klöting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005, 54: 2911–6.

    Article  PubMed  CAS  Google Scholar 

  14. Pagano C, Pilon C, Olivieri M, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006, 91: 3165–70.

    Article  PubMed  CAS  Google Scholar 

  15. Panidis D, Farmakiotis D, Rousso D, et al. Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med 2008, 19: 406–12.

    Article  PubMed  CAS  Google Scholar 

  16. Dıkmen E, Tarkun I, Cantürk Z, Cetınarslan B. Plasma visfatin level in women with polycystic ovary syndrome. Gynecol Endocrinol 2010, 27: 475–9.

    Article  PubMed  CAS  Google Scholar 

  17. Kim HM, Park J, Ryu SY, Kim J. The effect of menopause on the metabolic syndrome among Korean women: the Korean National Health and Nutrition Examination Survey, 2001. Diabetes Care 2007, 30: 701–6.

    Article  PubMed  CAS  Google Scholar 

  18. Lin JW, Caffrey JL, Chang MH, Lin YS. Sex, menopause, metabolic syndrome, and all-cause and cause specific mortality-cohort analysis from the Third National Health and Nutrition Examination Survey. J Clin Endocrinol Metab 2010, 95: 4258–67.

    Article  PubMed  CAS  Google Scholar 

  19. Chu MC, Cosper P, Nakhuda GS, Lobo RA. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertil Steril 2006, 86: 1669–75.

    Article  PubMed  CAS  Google Scholar 

  20. Sowers M, Zheng H, Tomey K, et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 2007, 92: 895–901.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  21. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006, 295: 1288–99.

    Article  PubMed  CAS  Google Scholar 

  22. Birkeland KI, Hanssen KF, Torjesen PA, Vaaler S. Level of sex hormone-binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 1993, 76: 275–8.

    PubMed  CAS  Google Scholar 

  23. Golden SH, Maguire A, Ding J, et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol 2002, 155: 437–45.

    Article  PubMed  Google Scholar 

  24. Reinecke H, Bogdanski J, Woltering A, et al. Relation of serum levels of sex hormone binding globulin to coronary heart disease in postmenopausal women. Am J Cardiol 2002, 90: 364–8.

    Article  PubMed  CAS  Google Scholar 

  25. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL; Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002, 25: 55–60.

    Article  PubMed  CAS  Google Scholar 

  26. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004, 110: 380–5.

    Article  PubMed  CAS  Google Scholar 

  27. Seo JA, Jang ES, Kim BG, et al. Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women. Diabetes Res Clin Pract 2008, 79: 108–11.

    Article  PubMed  CAS  Google Scholar 

  28. Gen R, Akbay E, Muslu N, Sezer K, Cayan F. Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance. Gynecol Endocrinol 2009, 25: 241–56.

    Article  PubMed  CAS  Google Scholar 

  29. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 2007, 67: 796–800.

    Article  CAS  Google Scholar 

  30. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 200, 163: 427–36.

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Istanbul Bilim University, Kısıklı cad. No:106 Altunizade, 34692, Istanbul, Turkey

    N. Güdücü MD, H. İşçi, A. B. Yiğiter & İ. Dünder

  2. Department of Biochemistry, Istanbul Bilim University, Avrupa Hospital, Istanbul, Turkey

    U. Görmüş

Authors
  1. N. Güdücü MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. İşçi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U. Görmüş
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. B. Yiğiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. İ. Dünder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Güdücü MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Güdücü, N., İşçi, H., Görmüş, U. et al. Serum visfatin levels do not increase in post-menopausal women with metabolic syndrome. J Endocrinol Invest 36, 157–161 (2013). https://doi.org/10.1007/BF03346752

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346752

Key-words

Search

Navigation